EUVIMEDEUVIMED entdecken
Crossref

Prospects for the use of mesenchymal stromal cells in the treatment of dilated cardiomyopathy

Zekhra E. Mirzezade, Olga V. Payushina, Dibakhan A. Tsomartova, Yelizaveta V. Chereshneva, Nataliya L. Kartashkina, Elina S. Tsomartova, Svetlana A. Kosobutskaya

Genes & Cells · 10.03.2026 · 21 (1) · 5-16

DOI: 10.17816/gc696289 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Genes & Cells, online erschienen am 10.03.2026. Verfasst von Zekhra E. Mirzezade und 6 weiteren Autor:innen. Die Arbeit nennt 64 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This review discusses the mechanisms underlying the therapeutic effects and the clinical prospects of mesenchymal stromal cell (MSC) transplantation in dilated cardiomyopathy. The development of dilated cardiomyopathy is based on a complex interplay of multiple etiological factors and mechanisms. This condition is characterized by high prevalence, unfavorable prognosis, and substantial mortality, highlighting the need for innovative treatment methods. In dilated cardiomyopathy, mesenchymal stromal cells exert multifaceted effects on the injured myocardium, primarily through paracrine secretion of cytoprotective, immunomodulatory, proangiogenic, and antifibrotic factors; suppression of oxidative stress; and restoration of cardiomyocyte energy metabolism. Preclinical and clinical studies have demonstrated the ability of mesenchymal stromal cells to improve cardiac contractile function and patients’ quality of life. Sustained long-term benefits have been reported, with allogeneic cells showing greater therapeutic potential and a lower incidence of complications compared with autologous cells. To enhance the efficacy of MSC transplantation and facilitate its broader implementation in clinical practice, several challenges must be addressed, including optimization of cell sources, delivery methods, and strategies to improve cell survival within the hostile myocardial microenvironment. In this context, genetic modification of mesenchymal stromal cells aimed at enhancing their cardioprotective and regenerative properties represents a promising approach to improving outcomes in patients with dilated cardiomyopathy.

Zitieren

APA

Mirzezade, Z. E., Payushina, O. V., Tsomartova, D. A., Chereshneva, Y. V., Kartashkina, N. L., Tsomartova, E. S., & Kosobutskaya, S. A. (2026). Prospects for the use of mesenchymal stromal cells in the treatment of dilated cardiomyopathy. Genes & Cells, 21(1), 5-16. https://doi.org/10.17816/gc696289

Vancouver

Mirzezade ZE, Payushina OV, Tsomartova DA, Chereshneva YV, Kartashkina NL, Tsomartova ES, et al. Prospects for the use of mesenchymal stromal cells in the treatment of dilated cardiomyopathy. Genes & Cells. 2026;21(1):5-16. doi:10.17816/gc696289

BibTeX
@article{Mirzezade2026,
  author = {Mirzezade, Zekhra E. and Payushina, Olga V. and Tsomartova, Dibakhan A. and Chereshneva, Yelizaveta V. and Kartashkina, Nataliya L. and Tsomartova, Elina S. and Kosobutskaya, Svetlana A.},
  title = {Prospects for the use of mesenchymal stromal cells in the treatment of dilated cardiomyopathy},
  journal = {Genes & Cells},
  year = {2026},
  volume = {21},
  number = {1},
  pages = {5--16},
  doi = {10.17816/gc696289}
}
Kostenlos starten →